X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
nccn-ipi (40) 40
index medicus (27) 27
humans (23) 23
oncology (23) 23
prognosis (23) 23
hematology (22) 22
lymphomas (20) 20
female (18) 18
survival (18) 18
aged (17) 17
chemotherapy (17) 17
male (17) 17
rituximab (17) 17
middle aged (16) 16
adult (14) 14
diffuse large b-cell lymphoma (14) 14
cancer (13) 13
lymphoma, large b-cell, diffuse - drug therapy (13) 13
diffuse large b cell lymphoma (12) 12
non-hodgkins-lymphoma (12) 12
r-chop (12) 12
analysis (11) 11
b-cell lymphoma (11) 11
elderly-patients (11) 11
lymphoma (11) 11
lymphoma, large b-cell, diffuse - pathology (11) 11
retrospective studies (11) 11
aged, 80 and over (10) 10
dlbcl (10) 10
international prognostic index (10) 10
lymphoma, large b-cell, diffuse - diagnosis (10) 10
lymphoma, large b-cell, diffuse - mortality (9) 9
rituximab era (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
lymphocytes b (7) 7
patients (7) 7
care and treatment (6) 6
index nccn-ipi (6) 6
medical prognosis (6) 6
medicine & public health (6) 6
patient outcomes (6) 6
r-ipi (6) 6
risk factors (6) 6
young adult (6) 6
adolescent (5) 5
albumin (5) 5
disease-free survival (5) 5
medical research (5) 5
medicine, experimental (5) 5
survival rate (5) 5
antibodies, monoclonal, murine-derived - therapeutic use (4) 4
comorbidity (4) 4
cyclophosphamide - therapeutic use (4) 4
diagnosis (4) 4
diffuse large b‐cell lymphoma (4) 4
doxorubicin - therapeutic use (4) 4
expression (4) 4
ipi (4) 4
medicine, research & experimental (4) 4
multivariate analysis (4) 4
pet imaging (4) 4
positron-emission-tomography (4) 4
prednisone - therapeutic use (4) 4
risk groups (4) 4
survival analysis (4) 4
treatment outcome (4) 4
vincristine - therapeutic use (4) 4
age (3) 3
anthracyclines (3) 3
breast-cancer (3) 3
chemotherapy plus rituximab (3) 3
chop (3) 3
classification (3) 3
elderly (3) 3
era (3) 3
gene-expression (3) 3
health risk assessment (3) 3
hemic and lymphatic diseases (3) 3
internal medicine (3) 3
lymphoma, large b-cell, diffuse - blood (3) 3
nccn‐ipi (3) 3
neoplasm staging (3) 3
non-hodgkin's lymphomas (3) 3
patients older (3) 3
predictor (3) 3
public, environmental & occupational health (3) 3
randomized controlled-trial (3) 3
research (3) 3
risk (3) 3
risk assessment (3) 3
trial (3) 3
absolute lymphocyte (2) 2
aged patients (2) 2
anthracycline (2) 2
antibodies, monoclonal, murine-derived - administration & dosage (2) 2
antibodies, monoclonal, murine-derived - adverse effects (2) 2
antineoplastic agents - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 11/2018, Volume 36, Issue 32, pp. 3271 - 3272
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 11/2018, Volume 36, Issue 32, pp. 3274 - 3274
Journal Article
BRITISH JOURNAL OF HAEMATOLOGY, ISSN 0007-1048, 01/2015, Volume 168, Issue 2, pp. 239 - 245
The International Prognostic Index (IPI) has been used for decades in diffuse large B-cell lymphoma (DLBCL). A retrospective cancer registry analysis in North... 
microglobulin | UNITED-STATES | SURVIVAL | B-CELL LYMPHOMA | diffuse large B cell lymphoma | elderly | RITUXIMAB | NCCN-IPI | albumin | NON-HODGKINS-LYMPHOMA | CARDIOTOXICITY | HEMATOLOGY
Journal Article
Leukemia Research Reports, ISSN 2213-0489, 2019, Volume 12, p. 100173
Neutrophil-to-lymphocyte ratio (NLR) has been recognized as a poor prognostic indicator in various solid tumors. We retrospectively analyzed 530 patients with... 
Neutrophil-to-lymphocyte ratio | Diffuse large B cell lymphoma | NCCN-IPI
Journal Article
British Journal of Haematology, ISSN 0007-1048, 08/2018, Volume 182, Issue 4, pp. 534 - 541
The Grupo Español de Linfomas y Trasplantes de Médula Ósea International Prognostic Index ( GELTAMO ‐ IPI ) stratifies four risk groups in diffuse large B cell... 
cell of origin subtyping | GELTAMO | IPI | Hans algorithm | immunohistochemistry | diffuse large B cell lymphoma | GELTAMO-IPI | SURVIVAL | DLBCL | PARAFFIN-EMBEDDED TISSUE | RITUXIMAB | NCCN-IPI | GENE-EXPRESSION | HEMATOLOGY | Immunohistochemistry | Lymphomas | Algorithms | Analysis | Regression models | Lymphocytes B | Risk groups | Risk | Health risk assessment | Lymphoma | Patients | B-cell lymphoma
Journal Article
HEMATOLOGICAL ONCOLOGY, ISSN 0278-0232, 02/2018, Volume 36, Issue 1, pp. 84 - 92
Little information is available on the very elderly patients with diffuse large B-cell lymphoma (DLBCL). We performed a retrospective analysis of 281 patients... 
DLBCL | elderly | R-CHOP | NCCN-IPI | COMPREHENSIVE GERIATRIC ASSESSMENT | SINGLE-ARM | CHEMOTHERAPY | TRIAL | INTERGRUPPO ITALIANO LINFOMI | anthracycline | ONCOLOGY | International Prognostic Index | RITUXIMAB | NON-HODGKINS-LYMPHOMA | HEMATOLOGY | ELDERLY-PATIENTS
Journal Article
Annals of Hematology, ISSN 0939-5555, 8/2019, Volume 98, Issue 8, pp. 1937 - 1946
The identification of high-risk patients deserving alternative first-line treatments to R-CHOP is a research priority in diffuse large B cell lymphoma (DLBCL).... 
High risk | Medicine & Public Health | Hematology | Outcome | GELTAMO-IPI | NCCN-IPI | Oncology | Diffuse large B cell lymphoma | OF-ORIGIN | RESPONSE CRITERIA | CLASSIFICATION | INTERNATIONAL PROGNOSTIC INDEX | RITUXIMAB | MYC | BCL2 | HEMATOLOGY | EXPRESSION | R-IPI | Medicine, Experimental | Medical research | Lymphomas | Risk factors | Medical prognosis | Identification
Journal Article
Blood Research, ISSN 2287-979X, 2017, Volume 52, Issue 4, pp. 276 - 284
The International Prognostic Index (IPI) has been a useful tool for predicting the prognosis of aggressive non-Hodgkin lymphoma in the last 20 years. Herein,... 
Prognostic index | β2-microglobulin | NCCN-IPI | Diffuse large B-cell lymphoma | Original
Journal Article
HEMATOLOGICAL ONCOLOGY, ISSN 0278-0232, 12/2017, Volume 35, Issue 4, pp. 440 - 446
Previous reports have evaluated the prognostic value of serum beta-2 microglobulin (B2MG) level in patients with non-Hodgkin lymphoma. However, its role in... 
SURVIVAL | R-CHOP | NCCN-IPI | SERUM BETA-2-MICROGLOBULIN | TISSUE LYMPHOMA | diffuse large B-cell lymphoma | prognosis | CHEMOTHERAPY | BETA-MICROGLOBULIN | HODGKINS-LYMPHOMA | ONCOLOGY | RITUXIMAB | beta-2 microglobulin | nevi risk model | HEMATOLOGY | ELDERLY-PATIENTS
Journal Article
British Journal of Haematology, ISSN 0007-1048, 12/2016, Volume 175, Issue 5, pp. 876 - 883
Journal Article
Cancer Medicine, ISSN 2045-7634, 09/2019, Volume 8, Issue 11, pp. 5137 - 5147
In the era of rituximab, the International Prognostic Index (IPI) has been inefficient in initial risk stratification for patients with R‐CHOP‐treated diffuse... 
total lesion glycolysis | diffuse large B‐cell lymphoma | prognostic model | metabolic tumor volume | PET/CT QUANTIZATION PARAMETERS | POSITRON-EMISSION-TOMOGRAPHY | ONCOLOGY | R-CHOP | RESPONSE ASSESSMENT | CONSENSUS | diffuse large B-cell lymphoma | INDEX NCCN-IPI | Index Medicus
Journal Article
Journal Article
Annals of Oncology, ISSN 0923-7534, 12/2014, Volume 25, Issue 12, pp. 2398 - 2404
Background: In the rituximab era, the conventional International Prognostic index (IPI) lost at least in part its predictive power, while the National... 
localized | IPI | rituximab | lymphoma | NCCN-IPI | OPEN-LABEL | CHEMOTHERAPY | YOUNG | ONCOLOGY | NON-HODGKINS-LYMPHOMA | CHOP | RADIOTHERAPY | RITUXIMAB ERA | Prognosis | Lymphoma, Large B-Cell, Diffuse - pathology | Humans | Middle Aged | Adult | Female | Male | Aged | Retrospective Studies | Index Medicus
Journal Article